| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Clinical Chemist |
 |
AACC Award Winners, 2000 |
|---|
 Top AACC Award Winners, 2000 |
|---|
Dr. Gochman began participating in the activities of the Capital Section of the AACC and was elected Chairman for the 1971–1972 term. It was at this time that he also became involved in the NCCLS and its standardization activities, and was elected President for the 1974–1976 term. In 1972, he moved to San Diego to join the University of California School of Medicine and the VA Medical Center in La Jolla. Dr. Gochman held several faculty positions, including adjunct professor of pathology, while serving as chief of the clinical chemistry laboratory at the hospital. In addition to his ongoing research, teaching, and service activities, he also conducted a postdoctoral training program in clinical chemistry. Among his trainees was Dr. Lemuel Bowie, who later was to serve as AACC President.
Dr. Gochman continued to participate in various AACC activities, including the Standards Committee and efforts to develop reference methods for uric acid and glucose. He was a Councilor for the Southern California Section of the AACC, Symposium Chairman for the 1974 Annual Meeting in Las Vegas, and served on the Editorial Board of Clinical Chemistry from 1974 to 1979. His relationship with colleagues from the NIH continued with participation on advisory groups for the Lipid Research Clinics Program and the National Cooperative Gallstone Study. Dr. Gochman was elected to serve as AACC President in 1978, a time when the Association was growing rapidly and hospital-based clinical chemists made up one-half of the membership.
In 1982, Dr. Gochman joined Beckman Instruments (now Beckman Coulter)
to resume a career in science and business closely connected to his
interests in clinical chemistry instrumentation. He has had management
roles in research and development, applications, technical support, and
professional relations. He continues to be involved in professional
organization activities and serves as company delegate to the NCCLS and
the IFCC. He participated in the AACC Task Force on the Changing
Practice Environment and the Delta Group (1995–1996), and presently is
a member of the Board of Trustees of the Van Slyke Society. He was the
AACC Liaison to the CAP Instrumentation Resource Committee through 1989
and has since been a Consultant Member. Dr. Gochman has published
extensively on clinical chemistry methodology and automation, and is an
internationally recognized speaker on these topics. 
|
AACC Award for Outstanding Contributions through Service to the
Profession of Clinical Chemistry
Mary F. Burritt, PhD, FACB, will receive the 35th annual award, sponsored by
Beckman Coulter, Inc. Dr. Burritt is the Associate Dean of the Mayo
School of Health Related Sciences and Professor of Laboratory Medicine
at the Mayo Clinic in Rochester, Minnesota. In addition, she is the
Medical Co-Director of the Central Clinical Laboratory, Director of the
Metals Laboratory, and Consultant for the Hospital Clinical
Laboratories at the Mayo Clinic. She received her BA in Chemistry from
Clarke College, Dubuque, Iowa, and her PhD in Biological Chemistry from
the University of Illinois Medical Center in Chicago. After completing
a 2-year postdoctoral fellowship in Immunology, she trained for an
additional 2 years in Clinical Chemistry, both at the Mayo Clinic.
Dr. Burritt has been active in AACC since becoming a member in 1978. She has served as a charter member and first Chair of the Electrolyte/Blood Gas Division (1986–1989) and as a member and Chair of the Long Range Planning Committee (1988–1990 and 1993–1994). In 1991, she served as the first Chair of the newly reorganized House of Delegates and as a member of the Strategic Analysis Task Force. She was elected to the Board of Directors in 1992, and in 1996 served as President of the Association. Dr. Burritt was the EduTrak Co-Chair for the 1998 AACC Annual Meeting, a member of the Task Force on Governance, and Chair of the Governance Implementation Task Force. She currently is serving as the Chair of the 2000 Annual Meeting Organizing Committee and as a member of the Meetings Management Group. Dr. Burritt has served as the AACC representative to the IFCC and as Chair of the IFCC Nominations Committee (1997–1999); she recently was appointed as Chair of the Visiting Lecturer Program and member of the Education Management Division of the IFCC. She also serves as the AACC representative and a member of the Executive Committee of the US Technical Advisory Group of ISO TC/212.
Dr. Burritt is also active in NCCLS, having served as Chair of the Subcommittee on Electrolytes (1987–1988) and as Chair of the Area Committee on Clinical Chemistry (1989–1993). She currently is an advisor on the Area Committee on Automation and a member of the Subcommittee on Electromechanical Interfaces. She also was a member of the Program Committee for the 1998 and 1999 NCCLS Annual Meetings, and currently is a member of the Volunteer Resources Committee. She is a member of the National Academy of Clinical Biochemistry, where she has served as a member of the Program Committees for several Point-of-Care Testing Meetings and currently serves on the Board of Directors. In addition, she is a member of the Academy of Clinical Laboratory Physicians and Scientists as well as the Mayo Foundation Chapter of Sigma Xi, for which she served as President in 1991. In 1996, Dr. Burritt was appointed to a 4-year term on the Clinical Laboratory Improvement Advisory Committee (CLIAC), which provides scientific and technical advice to the Secretary, Department of Health and Human Services, and the Director of the CDC.
Dr. Burritt has focused her research and education interests on
electrolytes (particularly ionized calcium), circadian rhythms of
calcium and bone markers, and point-of-care testing. She has authored
or co-authored more than 140 scientific articles, abstracts, and book
chapters, and has lectured extensively. She is the recipient of an AACC
Outstanding Speaker Award, the 1994 Streck Lectureship Award for
Distinguished Contributions to Biochemistry and Clinical Chemistry from
the University of Nebraska-Lincoln, the 1995 Gerulat Memorial Award
from the New Jersey Section of the AACC for outstanding achievement in
clinical chemistry, and in 1997 was given the AACC Past President’s
Award.
|
AACC Award for Outstanding Contributions in Education
Mitchell G. Scott, PhD, FACB, DABCC, will receive the 30th annual award, sponsored
by Quest Diagnostics Incorporated. Dr. Scott is Associate Professor in
the Division of Laboratory Medicine, Department of Pathology and
Immunology at Washington University School of Medicine, and Associate
Medical Director of Clinical Chemistry at Barnes-Jewish Hospital, St.
Louis, Missouri. A medical technologist at Barnes Hospital for 3 years
prior to attending graduate school, Dr. Scott received his PhD in
Immunology from Washington University in 1982, and then was a
postdoctoral fellow in Clinical Chemistry at Washington University. He
joined Mallinckrodt, Inc. as Research Manager of Hybridoma Sciences in
1984 and returned to Washington University as a faculty member in 1987.
A member of AACC since 1982, Dr. Scott has served AACC in a number of capacities at the local and national levels. He was a member (1990–1995) and Chair (1992–1995) of the Membership Committee and a member of the Commission on Professional and Membership Affairs (1992–1995). He served on the Task Force on Training Clinical Chemists (1992), the Task Force on Governance Structure (1997), the Nominating Committee (1996–1997), and the Oak Ridge Organizing Committee (1995–2000). He currently is a member of the Meetings Management Group and the Program Coordinating Commission, and is Chair of the Divisions Management Group. Locally he served as Midwest Section Program Chair (1989), Secretary (1993–1995), and Chair (1996). He has served on the Editorial Board of Clinical Chemistry since 1997 and currently is Reviews Co-Editor. Outside of AACC, he is Secretary/Treasurer of the Commission on Accreditation in Clinical Chemistry (COMACC) and President of the American Board of Clinical Chemistry (ABCC). He also is a member of the American Association of Immunologists, the Clinical Immunology Society, and the Academy of Clinical Laboratory Physicians and Scientists.
Dr. Scott is co-director of the clinical chemistry postdoctoral
training program at Washington University and since 1987 has had a
major role in training 33 postdoctoral fellows and 65 pathology
residents in clinical chemistry. His proudest accomplishments are that
more than 95% of the fellows and residents he has helped train are
active, productive members of our profession and that he has had a role
in continuing the strong tradition of laboratory medicine education at
Washington University. He spends considerable effort recruiting young
scientists who are basic science graduates to the training program at
Washington University as well as to other training programs around the
nation. His roles with COMACC and ABCC have also had an impact on the
focus and direction of clinical laboratory scientist training. His
research has focused on antibody variable region gene expression to
carbohydrate antigens and on the utility and interpretation of a
variety of clinical biochemical testing methods and approaches.
Together with many collaborators, he has authored 68 original
scientific papers, 22 reviews or textbook chapters, and 62 abstracts in
the basic and clinical sciences.
|
AACC Award for Outstanding Contributions to Clinical Chemistry in a
Selected Area of Research
Alfred H. Free, PhD, was selected to receive the 28th annual award, sponsored
by Roche Diagnostics Corp. Dr. Free, who passed away in May, was best
known for his work as inventor and developer of the dry reagent
urinalysis dipsticks that have had a major place in laboratory medicine
since the mid-1950s.
Dr. Free received an AB in Chemistry with honors from Miami University in Oxford, Ohio, and an MS and PhD in Biochemistry from Western Reserve University in Cleveland. He served as a research assistant at the Cleveland Clinic, in various teaching capacities at Western Reserve University, and as a consultant to BenVenue Laboratories, a producer of human blood plasma and penicillin, during World War II. In this latter position, he made important contributions to the development of lyophilization of human plasma for field transfusion and to the early production of antibiotics.
In 1946, Dr. Free joined the Ames Division of Miles Laboratories (now a part of the Bayer Corporation), and over time rose to head the research laboratory. In 1972, he became Vice President for Technical Services and Scientific Relations. Dr. Free made many contributions in a career that extended for 60 years, but it was from his posts at this corporation that he left his indelible mark.
Dr. Free introduced the idea that important analytes in urine could be tested on a strip of paper impregnated with chemicals that would produce color changes with differing amounts of analyte in the urine—an idea that became the now ubiquitous urine dipstick. In 1946, he developed dry reagent chemistries for semiquantitative detection of blood in urine, and in subsequent years followed this with chemistries for ketones, albumin, and bilirubin. He expanded this technology to the dry reagent strips we now call dipsticks with the introduction of CLINISTIX for urine glucose in 1956 and went on to add a range of chemistries to dipsticks. He also conceived the idea for multiple reagent pad strips for chemical urinalysis. Dr. Free also provided key leadership in developing the clinical concepts for the use of CLINISTIX and in introducing them into physicians’ offices worldwide. Today, this technology remains among the very first tests in the routine evaluation of any patient, in any part of the world. In 1997, on the 25th anniversary of the first instrument used for reading dry reagent strips, the CLINITEK Reflectance Urinalysis Analyzer, it was estimated that the Bayer Corporation had distributed more than 20 billion multiple reagent urinalysis strips and more than 100 000 CLINITEK instruments. The portability and low cost of dipsticks have allowed worldwide testing for major public health conditions, contributing in a major way to the improvement of healthcare worldwide.
Dr. Free was the author or co-author of more than 200 scientific papers and the holder of 15 major patents. He formed an extraordinary partnership with his wife Helen, who has also served the profession of clinical chemistry as president of the AACC and of the American Chemical Society.
In addition to his substantial scientific, clinical, and commercial
contributions, Dr. Free was an important participant in the activities
of the AACC, American Association for the Advancement of Science,
American Chemical Society, Association of Clinical Scientists, American
Board of Clinical Chemistry, and many other scientific and civic
organizations. He served the AACC in many capacities, for example,
serving as Chair of the Task Force on Membership Awareness, of the
International Relations Committee, of the Membership Committee, and of
the Chicago Local Section. His many honors ranged from election to the
Engineering and Science Hall of Fame to receiving the AACC Award for
Outstanding Contributions through Service to the Profession of Clinical
Chemistry to being recognized with an award from the local Lions Club
chapter as Citizen of the Year of Elkhart, Indiana. In June 2000, he
was inducted posthumously into the Inventors Hall of Fame.
|
AACC Award For Outstanding Scientific Achievements by a Young Investigator
Sridevi Devaraj, PhD, FACB, will receive the 25th annual award, sponsored by
Roche Diagnostics Corp. Dr. Devaraj graduated from the University of
Madras, India. Thereafter she trained in the areas of clinical
biochemistry and nutrition. She undertook fellowships at the Center for
Human Nutrition and in the Division of Clinical Chemistry at the
University of Texas Southwestern Medical Center at Dallas. She then
joined the faculty of The University of Texas Southwestern Medical
Center at Dallas in 1997 as an Instructor. She currently is Assistant
Professor of Pathology and Associate Director of the Chemistry
Laboratory at Parkland Health and Hospital Systems, Dallas, Texas.
Dr. Devaraj’s major research interests are the clinical biochemistry
of atherosclerosis and its modulation by antioxidants. She recently
received a Beginning Grant in Aid from the American Heart Association.
To date, she has 51 original papers and invited reviews that have been
published or are in press in the areas of nutrition, atherosclerosis,
and metabolism. She has received awards for her work, including the
George Grannis Award from the National Academy of Clinical Biochemistry
and the Merck Young Investigator Award for Atherosclerosis. She
currently is a Fellow of the American Heart Association and the
National Academy of Clinical Biochemistry, and is a member of AACC.
|
AACC Internatonal Travel Fellowship
Daniel Mazziotta, MD, will receive the 22nd annual award, sponsored by BD
Vacutainer Systems, Preanalytical Solutions of Becton
Dickinson and Company. Dr. Mazziotta graduated from the National
University of La Plata in 1974 and 1976, respectively. He has been
Professor of Clinical Chemistry at the National University of La Plata
since 1989.
After receiving training in several hospitals (general and pediatric), Dr. Mazziotta went to work at the Laboratory of Blood Gases and Electrolytes, Service for Lung and Heart Functional Exploration, Hospital San Juan de Dios of La Plata until 1980, providing laboratory service to the Intensive Care Unit. In 1978, he became interested in quality control, first in the Laboratory of Blood Gases and Electrolytes and later in the general clinical laboratory. At the end of 1980, he worked for the Ministry of Health of the Province of Buenos Aires, organizing the External Quality Control Program for public laboratories until 1985.
In 1986, Dr. Mazziotta moved to a professional institution and was nominated as Secretary of the Biochemical Federation of the Province of Buenos Aires, where he served until 1992. In 1987, he designed and directed the External Quality Assessment Scheme for clinical laboratories of the Biochemical Federation of Province of Buenos Aires, a position that he still holds after moving the EQAS to the Argentine Biochemical Foundation. He gained experience in preparing control materials to be used in EQAS for Clinical Chemistry and other laboratory specialties (Hematology, Urinalysis, and Instrumental).
During the 1990s, Dr. Mazziotta also became very active in teaching postgraduate courses in Quality Assurance in Argentina as well as many Latin-American countries: Bolivia, Uruguay, Paraguay, Dominican Republic, Mexico, Chile, Ecuador, and Guatemala. In the last two countries, he acted as Adviser and professor for the Pan American Health Organization in 1990 and 1992, respectively.
Dr. Mazziotta has been involved with the activities of the Latin-American Confederation of Clinical Biochemistry (COLABIOCLI), mainly since 1994 in the Continuous Quality Improvement Project for the Latin-American Region. He organized two Latin-American External Quality Surveys in 1992 and 1994, supported by the Biochemical Federation of Province of Buenos Aires. He has directed and given a special course for training organizers in EQAS Organization and Management every 2 years since 1996 with participants from Latin-American countries.
Since 1992, Dr. Mazziotta has been Corresponding Member, Member, and Chairman of the Committee on Analytical Quality, Education and Management Division of the International Federation of Clinical Chemistry and Laboratory Medicine. In 1997, he became Director of the Laboratory of Reference and Standardization in Clinical Biochemistry of the Argentine Biochemical Foundation, which was established through his initiative and is intended to be the basis of a Standardization Program in Clinical Laboratory in Argentina.
Since 1982, he has been a member of the Editorial Board of the
Acta Bioquímica Clínica Latinoamericana, the
official journal of the Latin-American Confederation of Clinical
Biochemistry. Since 1987, he has been a member of the Permanent
Scientific Commission, Argentine Section, of the same confederation.
Since 1998, he has been a member of the Advisory Board of the
Accreditation and Quality Assurance Journal. He has served as a member
of scientific committees at the national and international level, and
has acted as lecturer and chairman of numerous scientific meetings in
the Latin-American region. He has written or presented more than 40
papers, posters, and presentations on quality control and has
translated into Spanish documents and books related to the clinical
laboratory.
|
Outstanding Contribution for a Publication in the Journal Clinical Chemistry
Laurence Cole, PhD, will receive the first publication award, sponsored by
Diagnostics Products Corporation (DPC). Laurence Cole was born in the
United Kingdom and came to the United States in 1977. He obtained a PhD
in Biochemistry in 1982 at the Medical College of Wisconsin, in
Milwaukee. His mentor, Robert Hussa, PhD, was working on the structure
and synthesis of the hormone human chorionic gonadotropin (hCG) in
cancer cells. Laurence Cole was studying in the laboratories of Roland
Pattillo, MD, in the Department of Obstetrics and Gynecology, whose
principal interest was trophoblastic diseases and the establishment and
testing of choriocarcinoma cell lines (Jar, BeWo, JEG3, and others). It
was this environment that set Laurence Cole into a lifetime dedicated
to the physiology, immunochemistry, and biochemistry of hCG, and to the
study of trophoblastic diseases.
In 1982, Dr. Cole started working on a postdoctoral fellowship in the field of hCG and cancer and hCG and trophoblastic diseases in the Department of Pharmacology at University of Michigan in Ann Arbor, Michigan. In 1985, he moved to Yale University. For 14 years, Dr. Cole led a laboratory specializing in hCG biochemistry and immunoassay, conducting basic structural and physiological experiments and translation studies evaluating clinical applications. For most of the period, Dr. Cole was principal investigator on two consecutive National Institutes of Health grants. In response to demand, in January 1998 Dr. Cole started the USA hCG Reference Service, a consulting service running specialized hCG/hCG-related molecule tests, aiding physicians and clinical laboratories with interpretation of confusing commercial hCG assay results. In October 1999, Dr. Cole, his laboratory, and the hCG Reference Service moved to Albuquerque, New Mexico. Dr. Cole currently is Professor of Obstetrics and Gynecology, and of Biochemistry and Molecular Biology at the University of New Mexico, and Chief of the new Division of Women’s Health Research. His newest challenge is the expansion of a new women’s health research facility with a hallway of laboratories.
Dr. Cole has personally written (as first author or senior author) more than 100 articles on hCG structure, physiology, and immunoassay or on clinical applications of hCG or hCG-related molecules. He also has four active hCG-related patents. Dr. Cole’s early research included the original demonstration of the free ß-subunit of hCG in pregnancy serum (Cole et al., Endocrinology 1983;113:1176–8). hCG free ß-subunit is measured in serum today as a marker of Down syndrome. His early research also included the initial demonstration that free ß-subunit and ß-core fragment were useful as tumor markers in following cervical and other gynecological cancers (Cole et al., Cancer Res 1988;48:1356–60). Urinary ß-core fragment is now used, particularly in Japan, as a marker for managing advanced cervical cancer. Dr. Cole’s other research includes the first identification of abnormal O-linked sugar side chains on hCG produced by cancer cells (Cole LA. J Clin Endocrinol Metab 1987;65:811–3). A specific hCG assay that measures hCG with abnormal O-linked sugar side chains is used by the USA hCG Reference Service in identifying hCG of cancer origin.
In the 1990s, Dr. Cole’s team examined the structures of the various degradation products of hCG in serum and urine in normal pregnancy, abnormal pregnancy, and trophoblastic diseases. Specific degradation pathways were identified for hCG (Cole et al. J Clin Endocrinol Metab 1993;76:704–10); Dr. Cole’s team also studied the recognition, or lack of recognition of the different forms of hCG by various commercial hCG/hCGß immunoassays (Cole LA. Clin Chem 1997;43:2233–43). Other important works by Dr. Cole include the establishment of the complete peptide and N- and O-linked carbohydrate structures of hCG and its subunits from normal and abnormal pregnancies and trophoblastic diseases (Elliott et al. Endocr J 1977;7:15–32).
Dr. Cole’s recent work includes the identification of a unique hCG variant, hyperglycosylated hCG, in pregnancies with a Down syndrome fetus. Multiple translational studies were carried out. These showed that this single test can detect 80% of Down syndrome pregnancies (at a 5% false-positive rate) and that this test combined with other markers can detect >90% of Down syndrome cases at a 3% false-positive rate. The efficiency of this test and the combination of this test and others surpasses any previous marker or markers. This test currently is undergoing clinical evaluation for screening for Down syndrome in the state of California (Cole et al. Clin Chem 1999;45:2109–19). Other recent publications include the observation by the USA hCG Reference Service of 12 women with false-positive hCG test results. Seven of the 12 women underwent therapy, chemotherapy, hysterectomy, or other major surgery because of a false diagnosis of choriocarcinoma, based solely on multiple false-positive hCG results (Rotmensch and Cole. Lancet 2000;355:712–5).
Dr. Cole continues to carry out grant-funded research based around hCG.
Currently, he is examining the structure of hCG in hyperemesis
gravidarum in pregnancy and evaluating screening tests for
preeclampsia. The team is also investigating the role of hCG in
malignancy or invasion by trophoblastic cells.
|
The AACC Lectureship Award
David D. Ho, MD, will receive this year’s award, supported by an
educational grant from Bayer Diagnostics.
Dr. Ho received his BS in Physics from the California Institute of Technology and his MD from Harvard Medical School. He completed his residency at Cedars-Sinai Medical Center and UCLA School of Medicine in 1981. From 1982 to 1986, he was a clinical and research fellow in medicine and an instructor of medicine at Massachusetts General Hospital and Harvard. He was Associate Professor of Medicine at UCLA before joining New York University as Professor of Medicine and Microbiology and Co-Director of the Center for AIDS Research.
In 1990, he was selected to head the newly established Aaron Diamond AIDS Research Center in New York City. He currently is Director and Chief Executive Officer of that institution as well as a professor at The Rockefeller University.
Dr. Ho has spent his career in AIDS research, a field in which he has demonstrated such success that he was selected as Time magazine’s Man of the Year for 1996.
His interest in this disease began in the early 1980s, when he encountered patients in hospitals with a mysterious, fatal illness that only later would be identified and named AIDS. In the next few years at Harvard and UCLA, Dr. Ho studied the virus in addition to his other responsibilities. He was one of the first people in the world to isolate the AIDS-causing virus, HIV.
At the Aaron Diamond AIDS Research Center, he leads a team of some 50 world-class researchers studying this unique disease. Under Dr. Ho’s direction, researchers at the Diamond Center have elucidated how the virus replicates within the body, how it invades lymphocytes, and many other crucial aspects of its pathology.
But perhaps Dr. Ho’s most important contribution has been to overturn the conventional wisdom that the effects of the AIDS infection take years to surface because the virus is dormant in its early stages. Dr. Ho showed that the virus is always active and that the immune system is constantly fighting the virus off until it is finally overwhelmed. Based on this insight, Dr. Ho conceived the approach of attacking this fast-mutating virus with a combination of state-of-the-art drugs in the earliest stages of infection. The success of the drug cocktail treatment and other advances have fundamentally changed the way we view AIDS. Although we are still far from having a cure, we no longer regard this infection as the virtual death sentence it first appeared, and it is even possible to reduce the virus to undetectable concentrations in blood, semen, and lymph tissues.
Dr. Ho has received the Ernst Jung Prize in Medicine and the New York
City Mayor’s Award for Excellence in Science and Technology, and has
been elected to the Institute of Medicine of the National Academy of
Sciences. He is the author or co-author of more than 200 publications.
He has served on a variety of AIDS-related committees, including the
National Task Force on AIDS Drug Development.
|
AACC’s Past President’s Award
K. Michael Parker, PhD, DABCC, will receive this year’s award, sponsored by the
Allegiance Healthcare Corporation, a Cardinal Health company. Dr.
Parker has compiled a distinguished career in service to laboratory
medicine, professional organizations, and academic institutions. "I
have found that my career has provided me with the wonderful
opportunity to serve others", stated Dr. Parker as he reflected on
his professional pursuits during the last 28 years.
Dr. Parker is a tenured Professor of Pathology at the University of Oklahoma Health Sciences Center. He serves as Interim Chief of Clinical Laboratories, Director of Core Laboratory Operations, and Director of the Toxicology/Therapeutic Drug Monitoring Laboratory for University and Children’s Hospitals.
Dr. Parker earned a BS in Chemistry from Abilene Christian University and a PhD in Biochemistry from the University of Texas. He is certified as a Diplomate of the American Board of Clinical Chemistry and is a fellow of the National Academy of Clinical Biochemistry (NACB).
Dr. Parker served as the 50th President of the AACC in 1999. During his year as President, Dr. Parker focused many of his efforts on facilitating strategic planning by AACC’s Board of Directors, preparing the AACC and its members for the changing environment of laboratory medicine and communicating the value of laboratory testing and the laboratorian to those outside the profession. Dr. Parker launched the Association’s healthcare awareness campaign (Health Indicators 5 Program) at a Capitol Hill press conference with key House of Representative leaders.
Dr. Parker currently is a member of the Board of Directors of AACC and the NACB and serves as AACC’s representative to the International Federation of Clinical Chemistry and Laboratory Medicine. In the past, Dr. Parker has served in numerous other leadership roles for the AACC at the regional, national, and international levels. He has served the Texas Section in all elected positions (i.e., Secretary-Treasurer, Chair-Elect, and Chair) and has been appointed to key leadership assignments (e.g., Delegate and Legislative Liaison). He was honored by the Texas Section with the Outstanding Clinical Chemist Award in 1988 and the Chairman’s Award for Service in 1995. He has served as a member of numerous AACC committees and as Chair of several AACC groups. For example, he served as Chair of the 1988 Annual Meeting Organizing Committee, Chair of the House of Delegates, and Chair of the Delta Project. In 1994, he was honored for his service to the AACC with the national Award for Outstanding Contributions Through Service to the Profession of Clinical Chemistry.
Dr. Parker is active in the teaching programs at the University of Oklahoma Health Sciences Center. He coordinates several teaching activities for medical students and residents in the Department of Pathology as well as an elective in clinical pathology and a summer research program for medical students. He directs the resident training program in clinical chemistry and serves on the Residency Governance Committee and the Curriculum Committee for the Department of Pathology. His Department recognized his contributions to teaching with its Unsung Hero Award.
Dr. Parker’s research interests have been broad but have tended to focus in the areas of diabetes mellitus; drug use, abuse, and addiction; clinical toxicology and therapeutic drug monitoring; and applied investigations related to clinical laboratory medicine. He has contributed more than 70 publications in these areas. He serves as a scientific reviewer for Clinical Chemistry, Diabetes Care, and Annals of Clinical Biochemistry. During his tenure as Chair of the Delta Project, publication of the newsletter Clinical Laboratory Strategies was begun, and Dr. Parker served as Chair of its first Editorial Advisory Board from 1996 to 1997.
Dr. Parker’s professional career has been only one facet of his
multidimensional life. He enjoys time with friends and hobbies such as
sports, photography, woodworking, and music. His greatest joy is
spending time with his wife, two daughters, son-in-law, and a new
grandson.
|
Meetings
The 18th International Congress of Clinical Chemistry and
Laboratory Medicine will be held October 20–25, 2002, in Kyoto,
Japan. Contact: Secretariat of 18th ICCC 2002 Kyoto, c/o Center for
Academic Societies Japan, Osaka, 14F, Senri Life Science Center Bldg.,
1-4-2 Shinsenrihigashi-machi, Toyonaka, Osaka 560-0082, Japan. Phone
81-(0)6-6873-2301; fax 81-(0)6-6873-2300; e-mail ICCCKyoto@bcasj.or.jp.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
